Purchase this article with an account.
M. E. Torres, O. Ustáriz-Gonzáles, V. Kon-Jara, G. García-Aguirre, J. L. Díaz-Rubio, M. Gordon-Angelozzi, A. Solis-Vivanco, M. Ober, J. L. Guerrero-Naranjo, H. Quiroz-Mercado; Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):290.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the safety and efficacy of intravitreal bevacizumab as a new option in the treatment of chronic or recurrent central serous chorioretinopathy (CSC).
Prospective, non-comparative case series. Six eyes with chronic (> 6 months symptoms) or recurrent (> 1 episode) CSC were treated with intravitreal bevacizumab (2.5mg/0.1cc). ETDRS best corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICG) and optical coherent tomography (OCT) were evaluated in all cases at baseline and 1, 3, and 6 months after treatment.
Visual acuity improved in all cases at one month after treatment with resolution of symptoms and decreased neurosensory retinal and RPE detachment as demonstrated by OCT, as well as fluorescein leakage and choroidal hyperpermeability. There were no adverse events.
Intravitreal bevacizumab is well tolerated and resulted in a significant improvement in visual acuity, FA, ICG and OCT. Although these results are promising, definitive recommendations of treatment require further investigations.
This PDF is available to Subscribers Only